Patients with elevated levels of FOXK2 in adrenocortical carcinoma (ACC), KICH, BLCA, and uveal melanoma (UVM) have a worse prognosis than those with lower levels, as shown by both OS (p < 0.001) and DFS (p < 0.001) (Figure S2c–g), suggesting a negative outlook for tumor patients with high FOXK2 expression. This evidence concerns the gene FOXK2 and adrenal cortex carcinoma.